LIPM Inhibitors
LIPM inhibitors encompass a range of chemical compounds that impede various biochemical pathways, indirectly influencing LIPM's functional activity. Compounds such as Wortmannin and LY294002 operate by staunchly inhibiting the phosphoinositide 3-kinase (PI3K) pathway, a critical signaling cascade for cell survival and metabolism, which indirectly leads to a reduction in LIPM activity by dampening survival signals that might otherwise enhance its function. Similarly, Rapamycin's inhibition of the mTOR pathway, a downstream effect of PI3K/AKT signaling, curtails cellular growth and protein synthesis signals, thereby potentially diminishing LIPM's activity. The lipid metabolism pathway is another target for LIPM inhibitors; Palmitoyl-CoA, Triacsin C, and Perhexiline act by competitively inhibiting enzymes involved in lipid metabolism or bydirectly decreasing fatty acid oxidation, which in turn can attenuate LIPM's activity considering its role in lipid-related processes. Etomoxir and 5-(Tetradecyloxy)-2-furoic acid (TOFA) further inhibit components of lipid metabolism, with Etomoxir irreversibly inhibiting carnitine palmitoyltransferase 1 (CPT1) and TOFA targeting acetyl-CoA carboxylase (ACC), both leading to a potential decrease in LIPM activity due to alterations in lipid utilization and synthesis.
Moreover, inhibitors like GW4869 and Cerulenin disrupt specific aspects of lipid signaling and synthesis, respectively, with GW4869 acting on neutral sphingomyelinase (nSMase) affecting sphingolipid metabolism, and Cerulenin obstructing fatty acid synthase, thus potentially reducing the functional activity of LIPM if it is linked to these lipid pathways. Inhibitors that modulate the MAPK/ERK pathway, such as U0126 and PD98059, provide an indirect mechanism to diminish LIPM activity by influencing cellular responses to growth and stress signals, which may have downstream effects on LIPM's role in various cellular functions. Collectively, these inhibitors provide a multifaceted approach to modulating LIPM activity, targeting both upstream signaling events and direct metabolic pathways in which LIPM is implicated.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
This is a potent phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it prevents the activation of the AKT signaling pathway, which is important for numerous cellular processes, including metabolism and survival. Inhibition of this pathway can lead to reduced activity of LIPM due to diminished survival signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another specific inhibitor of PI3K, which leads to the blockade of the PI3K/AKT pathway, indirectly leading to the reduced activity of LIPM by impeding the survival and metabolic signals essential for LIPM's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it can block the downstream effects of the PI3K/AKT pathway, thereby reducing the activity of LIPM as a part of the broader inhibition of cellular growth and protein synthesis signals. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
This compound inhibits long-chain acyl-CoA synthetase. By inhibiting the synthesis of acyl-CoA, it can decrease lipid biosynthesis and metabolism, indirectly reducing the activity of LIPM involved in these processes. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $188.00 | ||
Perhexiline inhibits carnitine palmitoyltransferase (CPT1), a key enzyme in fatty acid oxidation. By reducing fatty acid oxidation, it may indirectly decrease LIPM activity by altering lipid metabolism. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 is an inhibitor of neutral sphingomyelinase (nSMase). By inhibiting nSMase, it can alter sphingolipid metabolism and signaling, which might indirectly reduce LIPM activity if LIPM is involved in related pathways. | ||||||
R-(+)-Etomoxir | 124083-20-1 | sc-208201A sc-208201 | 2 mg 5 mg | $245.00 $430.00 | ||
Etomoxir inhibits CPT1, but unlike Perhexiline, it is irreversible. It impedes fatty acid transport into mitochondria for β-oxidation, potentially reducing LIPM activity by altering lipid utilization and signaling. | ||||||
TOFA (5-(Tetradecyloxy)-2-furoic acid) | 54857-86-2 | sc-200653 sc-200653A | 10 mg 50 mg | $97.00 $374.00 | 15 | |
TOFA is an allosteric inhibitor of acetyl-CoA carboxylase (ACC). By inhibiting ACC, TOFA reduces malonyl-CoA levels, which can lead to decreased fatty acid synthesis and potentially less LIPM activity as a consequence of altered lipid metabolism. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which prevents the activation of the MAPK/ERK pathway. The suppression of this pathway can impact various cellular functions, possibly reducing LIPM activity by altering growth and differentiation signals. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor that specifically blocks the MAPK/ERK pathway. This could indirectly lower LIPM activity by modifying cellular responses to growth and stress signals. | ||||||